WallStSmart

Celestica Inc. (CLS)vsMedline Inc. Class A Common Stock (MDLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 111% more annual revenue ($29.14B vs $13.79B). CLS leads profitability with a 7.0% profit margin vs 3.3%. MDLN trades at a lower P/E of 36.7x. CLS earns a higher WallStSmart Score of 68/100 (B-).

CLS

Strong Buy

68

out of 100

Grade: B-

Growth: 10.0Profit: 7.0Value: 5.7Quality: 5.0
Piotroski: 5/9

MDLN

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 5.0Value: 6.3Quality: 6.8
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CLS.

MDLNUndervalued (+69.5%)

Margin of Safety

+69.5%

Fair Value

$147.84

Current Price

$39.25

$108.59 discount

UndervaluedFair: $147.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLS4 strengths · Avg: 9.5/10
Return on EquityProfitability
52.4%10/10

Every $100 of equity generates 52 in profit

Revenue GrowthGrowth
52.8%10/10

Revenue surging 52.8% year-over-year

EPS GrowthGrowth
147.3%10/10

Earnings expanding 147.3% YoY

PEG RatioValuation
1.008/10

Growing faster than its price suggests

MDLN2 strengths · Avg: 9.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Areas to Watch

CLS3 concerns · Avg: 2.3/10
Profit MarginProfitability
7.0%3/10

7.0% margin — thin

P/E RatioValuation
45.5x2/10

Premium valuation, high expectations priced in

Price/BookValuation
20.9x2/10

Trading at 20.9x book value

MDLN3 concerns · Avg: 3.3/10
P/E RatioValuation
36.7x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
6.0%3/10

ROE of 6.0% — below average capital efficiency

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : CLS

The strongest argument for CLS centers on Return on Equity, Revenue Growth, EPS Growth. Revenue growth of 52.8% demonstrates continued momentum. PEG of 1.00 suggests the stock is reasonably priced for its growth.

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bear Case : CLS

The primary concerns for CLS are Profit Margin, P/E Ratio, Price/Book. A P/E of 45.5x leaves little room for execution misses.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 3.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

CLS profiles as a hypergrowth stock while MDLN is a value play — different risk/reward profiles.

CLS is growing revenue faster at 52.8% — sustainability is the question.

MDLN generates stronger free cash flow (316M), providing more financial flexibility.

Monitor ELECTRONIC COMPONENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CLS scores higher overall (68/100 vs 52/100) and 52.8% revenue growth. MDLN offers better value entry with a 69.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Celestica Inc.

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Celestica Inc. provides hardware platforms and supply chain solutions in North America, Europe, and Asia. The company is headquartered in Toronto, Canada.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Want to dig deeper into these stocks?